SEARCH

SEARCH BY CITATION

References

  • 1
    Griffth JD, Comeau L, Rosenfield, Stansel RM, Bianchi A, Moss H, de Lange T. Mammalian telomeres in a large duplex loop. Cell 1999; 97: 50314.
  • 2
    Blackburn EH. Switching and signaling at the telomere. Cell 2001; 106: 66173.
  • 3
    de Lange T. Cell biology. Telomere capping—one strand fits all. Science 2001; 292: 10756.
  • 4
    van Steensel B, Smogorzewska A, de Lange T. TRF2 protects human telomeres from end-to-end fusions. Cell 1998; 92: 40113.
  • 5
    van Steensel B, de Lange T. Control of telomere length by the human telomeric protein TRF1. Nature 1997; 385: 7403.
  • 6
    de Lange T. Protection of mammalian telomeres. Oncogene 2002; 21: 53240.
  • 7
    Karlseder J. Telomere repeat binding factors: keeping the ends in check. Cancer Lett 2003; 194: 18997.
  • 8
    Rangan A, Fedoroff OY, Hurley LH. Induction of duplex to G-quadruplex transition in the c-myc promoter region by a small molecule. J Biol Chem 2001; 276: 46406.
  • 9
    Wright WE, Shay JW. Cellular senescence as a tumor-protection mechanism: the essential role of counting. Curr Opin Genet Dev 2001; 11: 98103.
  • 10
    Karlseder J, Smogorzewska A, de Lange T. Senescence induced by altered telomere state, not telomere loss. Science 2002: 295: 24469.
  • 11
    Classon M, Harlow E. The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer 2002; 2: 91017.
  • 12
    Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, Cordon-Cardo C, DePinho RA. The INK4a tumor suppressor gene product, ARF, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998; 92: 71323.
  • 13
    Zhu J, Woods D, McMahon M, Bishop JM. Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev 1998; 12: 29973007.
  • 14
    Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 1965; 37: 61436.
  • 15
    Shay JW, West MD, Wright WE. Re-expression of senescent markers in deinduced reversibly immortalized cells. Exp Gerontol 1992; 27: 47792.
  • 16
    IJpma AS, Greider CW. Short telomeres induce a DNA damage response in Saccharomyces cerevisiae. Mol Biol Cell 2003; 14: 9871001.
  • 17
    Xia SJ, Shammas MA, Shmooker Reis RJ. Reduced telomere length in ataxia-telangiectasia fibroblasts. Mutat Res 1996; 364: 111.
  • 18
    D'Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, Von Zglinicki T, Saretzki G, Carter NP, Jackson SP. A DNA damage checkpoint response in telomere-initiated senescence. Nature 2003; 426: 1948.
  • 19
    Counter CM, Avilion AA, Le Feuvre CE, Stewart NG, Greider CW, Harley CB, Bachetti S. Telomerase shortening associated with chromosome instability is arrested in immortal cells with express telomerase activity. EMBO J 1992; 11: 19219.
  • 20
    Artandi SE, Chang S, Lee SL, Alson S, Gottlieb GJ, Chin L, DePinho RA. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature 2000; 406: 6415.
  • 21
    DePinho RA. The age of cancer. Nature 2000; 408: 24854.
  • 22
    Hackett JA, Feldser DM, Greider CW. Telomere dysfunction increases mutation rate and genomic instability. Cell 2001; 106: 27586.
  • 23
    O'Hagan RC, Chang S, Maser RS, Mohan R, Artandi SE, Chin L, DePinho RA. Telomere dysfunction provokes regional amplification and deletion in cancer genomes. Cancer Cell 2002; 2: 14955.
  • 24
    Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, Orntoft T, Lukas J, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorogenesis. Nature 2005; 434: 86470.
  • 25
    Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, Venere M, Ditullio RA,Jr, Kastrinakis NG, Levy B, Kletsas D, Yoneta A, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005; 434: 90713.
  • 26
    Holt SE, Shay JW. Role of telomerase in cellular proliferation and cancer. J Cell Physiol 1999; 180: 1018.
  • 27
    Moro-Sibilot D, Fievet F, Jeanmart M, Lantuejoul S, Arbib F, Laverrière MH, Brambilla E, Brambilla C. Clinical prognostic indicators of high-grade pre-invasive bronchial lesions. Eur Respir J 2004; 24: 249.
  • 28
    Bailey SM, Brenneman MA, Goodwin EH. Frequent recombination in telomeric DNA may extend the proliferative life of telomerase-negative cells. Nucleic Acids Res 2004; 32: 374351.
  • 29
    Greider CW, Blackburn EH. A telomeric sequence in the RNA of Tetrahymena telomerase required for telomere repeat synthesis. Nature 1989; 337: 3317.
  • 30
    Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD, Ziawgra L, Beijersbergen RL, Davidoff MJ, Liu Q, Bacchetti S, Harber DA, et al. HEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 1997; 90: 78595.
  • 31
    Mitchell JR, Cheng J, Collins K. A box H/ACA small nucleolar RNA like domain at the human telomerase RNA 3′ end. Mol Cell Biol 1999; 19: 56776.
  • 32
    Broccoli D, Young JW, de Lange T. Telomerase activity in normal and malignant hematopoietic cells. Proc Natl Acad Sci USA 1995; 92: 90826.
  • 33
    Wright WE, Piatyszek MA, Rainey WE, Byrd W, Shay JW. Telomerase activity in human germline and embryonic tissues and cells. Dev Genet 1996; 18: 1739.
  • 34
    Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, Harley CB, Shay JW, Lichtsteiner S, Wright WE. Extension of life-span by introduction of telomerase into normal human cells. Science 1998; 279: 34952.
  • 35
    Smith CD, Smith DL, DeRisi JL, Blackburn EH. Telomeric protein distributions and remodeling through the cell cycle in Saccharomyces cerevisiae. Mol Biol Cell 2003; 14: 55670.
  • 36
    Zhang A, Zheng C, Lindvall C, Hou M, Ekedahl J, Lewensohn R, Zan Z, Yang X, Henriksson M, Blennow E, Nordenskjold M, Zetterberg A, et al. Frequent amplifcation of the telomerase reverse transcriptase gene in human tumors. Cancer Res 2000; 60: 62305.
  • 37
    Greenberg RA, O'Hagan RC, Deng HY, Xiao QR, Hann SR, Adams RR, Lichtsteiner S, Chin L, Morin GB, De Pinho RA. Telomerase transcriptase reverse gene is a direct target of c-myc but is not functionally equivalent to cellular transformation. Oncogene 1999; 18: 121926.
  • 38
    Oh S, Song YH, Yim J, Kim TK. Identification of Mad as a repressor of the human telomerase (hTERT) gene. Oncogene 2000; 19: 148590.
  • 39
    Kyo S, Takakura M, Taira T, Kanaya T, Itoh H, Yutsudo M, Ariga H, Inoue M. Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT). Nucleic Acids Res 2000; 28: 66977.
  • 40
    Zheng L, Lee WH. The retinoblastoma gene: a prototypic and multifunctional tumor suppressor. Exp Cell Res 2001; 264: 218.
  • 41
    Crowe DL, Nguyen DC. Rb and E2F1 regulate telomerase activity in human cancer cells. Biochim Biophys Acta 2001; 1518: 16.
  • 42
    Cong YS, Wright WE, Shay JW. Human telomerase and its regulation. Microbiol Mol Biol Rev 2002; 66: 40725.
  • 43
    Dessain SK, Yu HY, Reddel RR, Beijersbergen RL, Weinberg RA. Methylation of the human telomerase gene CpG island. Cancer Res 2000; 60: 53741.
  • 44
    Shin KH, Kang MK, Dicterow E, Park NH. Hypermethylation of the hTERT promoter inhibits the expression of telomerase activity in normal oral fibroblasts and senescent normal oral keratinocytes. Br J Cancer 2003; 89: 14738.
  • 45
    Guilleret I, Benhattar J. Demethylation of the human telomerase catalytic subunit (hTERT) gene promoter reduced hTERT expression and telomerase activity and shortened telomeres. Exp Cell Res 2003; 289: 32634.
  • 46
    Krams M, Hero B, Berthold F, Parwaresch R, Harms D, Rudolph P. Full-length telomerase reverse transcriptase messenger RNA is an independent prognostic factor in neuroblastoma. Am J Pathol 2003; 162: 101926.
  • 47
    Li H, Zhao LL, Funder JW, Liu JP. Telomerase is controlled by protein kinase C α in human breast cancer cells. J Biol Chem 1998; 273: 3343642.
  • 48
    Kang SS, Kwon T, Kwon DY, Do SI. Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit. J Biol Chem 1999; 274: 1308590.
  • 49
    Kharbanda S, Kumar V, Dhar S, Pandey P, Chen C, Majumber P, Yuan ZM, Whang Y, Strauss W, Pandita TK, Weaver D, Kufe D. Regulation of the hTERT telomerase catalytic subunit by the c-Abl tyrosine kinase. Curr Biol 2000; 10: 56875.
  • 50
    Etheridge KT, Banik SSR, Armbruster BN, Zhu Y, Terns RM, Terns MP, Counter CM. The nucleolar localization domain of the catalytic subunit of human telomerase. J Biol Chem 2002; 27: 2476470.
  • 51
    Wong JMY, Kusdra L, Collins K. Subnuclear shuttling of human telomerase induced by transformation and DNA damage. Nat Cell Biol 2002; 4: 7316.
  • 52
    Kumaki K, Kawai T, Hiroi S, Shinomiya N, Oseki Y, Ferrans VJ, Torikata C. Telomerase activity and expression of human telomerase RNA component and human telomerase reverse transcriptase in lung carcinomas. Hum Pathol 2001; 32: 18895.
  • 53
    Kumaki K, Kawai T, Churg A, Galateau-Sallé FB, Hasleton P, Henderson D, Roggli V, Travis WD, Cagle PT, Ferrans VJ. Expression of telomerase reverse transcriptase (TERT) in malignant mesotheliomas. Am J Surg Pathol 2002; 26: 36570.
  • 54
    Gomez-Roman JJ, Fontalba Romero A, Sanchez Castro L, Hernandez Nieto E, Fernandez-Luna JL, Val-Bernal JF. Telomerase activity in pulmonary neuroendocrine tumours. Am J Surg Pathol 2000; 24: 41721.
  • 55
    Nakanishi K, Kawai T, Kumaki F, Hirot S, Mukai M, Ikeda E. Expression of human telomerase RNA component and telomerase reverse transcriptase mRNA in atypical adenomatous hyperplasia of the lung. Hum Pathol 2002; 33: 697702.
  • 56
    Hiyama K, Hiyama E, Ishioka S, Yamakido M, Inai K, Gazdar AF, Piatyszek MA, Shay JW. Telomerase activity in small cell and non-small cell lung cancer. J Natl Cancer Inst 1995; 87: 895902.
  • 57
    Yashima K, Litzky LA, Kaiser L, Rogers T, Lam I, Wistuba II, Milchgrub S, Srivastava S, Piatyszek MA, Shay JW, Gazdar AF. Telomerase expression in respiratory epithelium during the multistage pathogenesis of lung carcinomas. Cancer Res 1997; 57: 23737.
  • 58
    Ahrendt SA, Yang SC, Wu L, Westra WH, Jen J, Califano JA, Sidransky D. Comparison of oncogene mutation detection and telomerase activity for the molecular staging of non small cell lung cancer. Clin Cancer Res 1997; 3: 120714.
  • 59
    Albanell J, Lonardo F, Rush V, Engelhardt M, Langenfeld J, Han W, Klimstra D, Venkatraman R, Moore MA, Dimitrovsky E. High telomerase activity in primary lung cancers: association with increased cell proliferation rates and advanced pathologic stage. J Natl Cancer Inst 1997; 89: 160915.
  • 60
    Fujiwara M, Okayasu I, Takemura T, Tanaka I, Masuda R, Furuhata Y, Noji M, Oritsu M, Kato M, Oshimura M. Telomerase activity significantly correlates with chromosome alterations, cell differentiation, and proliferation in lung adenocarcinoma. Mod Pathol 2000; 13: 7239.
  • 61
    Marchetti A, Bertacca G, Buttita F, Chella A, Quattrocolo G, Angeletti CA, Belivacqua G. Telomerase activity as a prognostic indicator in stage I non small cell lung cancer. Clin Cancer Res 1999; 5: 207781.
  • 62
    Marchetti A, Pellegrini C, Buttitta F, Falleni M, Romagnoli S, Felicioni L, Barassi F, Salvatore S, Chella A, Angelletti CA, Roncalli M, Coggi G, et al. Prediction of survival in stage I lung carcinoma patients by telomerase function evaluation. Lab Invest 2002; 82: 72936.
  • 63
    Wang L, Soria JC, Kemp BL, Liu DD, Mao L Khuri FR. hTERT expression is a prognostic factor of survival in patients with stage I non small cell lung cancer. Clin Cancer Res 2002; 8: 28839.
  • 64
    Xinarianos G, Scott FM, Liloglou T, Prime W, Callaghan J, Gosney JR, Field JK. Telomerase activity in non-small cell lung carcinomas correlates with smoking status. Int J Oncol 1999; 15: 9615.
  • 65
    Lantuejoul S, Soria JC, Moro-Sibilot D, Morat L, Veyrenc S, Lorimier P, Brichon PY, Sabatier L, Brambilla C, Brambilla E. Differential expression of telomerase reverse transcriptase (hTERT) in lung tumours. Br J Cancer 2004; 90: 12229.
  • 66
    Wu YL, Dudognon C, Nguyen E, Hillion J, Pendino F, Tarkanyi I, Aradi J, Lanotte M, Tong JH, Chen GQ, Segal-Bendirdjian E. Immunodetection of human telomerase reverse-transcriptase (hTERT) re-appraised: nucleolin and telomerase cross paths. J Cell Sci 2006; 119: 2797806.
  • 67
    Khurts S, Masutomi K, Delgermaa L, Arai K, Oishi N, Mizuno H, Hayashi N, Hahn WC, Murakami S. Nucleolin interacts with telomerase. J Biol Chem 2004; 279: 5150815.
  • 68
    Zaffaroni N, De Polo D, Villa R, Della Porta C, Collini P, Fabbri A, Pilotti S, Daidone MG. Differential expression of telomerase activity in neuroendocrine lung tumours: correlation with gene product immunophenotyping. J Pathol 2003; 201: 12733.
  • 69
    Zaffaroni N, Villa R, Pastorino U, Cirincione R, Incarbone M, Alloisio M, Curto M, Pilotti S, Daidone MG. Lack of telomerase activity in lung carcinoids is dependent on human telomerase reverse transcriptase transcription and alternative splicing and is associated with long telomeres. Clin Cancer Res 2005; 11: 28329.
  • 70
    Snijders PJ, van Duin M, Walboomers JM, Steenbergen RD, Risse EK, Helmerhorst TJ, Verheijen RH, Meijer CJ. Telomerase activity exclusively in cervical carcinomas and a subset of cervical intraepithelial neoplasia grade III lesions: strong association with elevated messenger RNA levels of its catalytic subunit and high risk human papillomavirus DNA. Cancer Res 1998; 58: 381218.
  • 71
    Kim HR, Christensen R, Park NH, Sapp P, Kang ML, Park NH. Elevated expression of hTERT is associated with dysplastic cell transformation during human oral carcinogenesis in situ. Clin Cancer Res 2001; 7: 307986.
  • 72
    Umbricht CB, Sherman ME, Dome J, Carey LA, Marks J, Kim N, Sukumar S. Telomerase activity in ductal carcinoma in situ and invasive breast cancer. Oncogene 1999; 18: 340714.
  • 73
    Shibya K, Fujisawa T, Hoshino, Baba M, Saitoh Y, Lizasa T, Sekine Y, Suzuki M, Hiroshima K, Ohwada H. Increased telomerase activity and elevated hTERT mRNA expression during multistage carcinogenesis of squamous cell carcinoma of the lung. Cancer 2001; 92: 84985.
  • 74
    Snijders PJ, Breuer RH, Sutedja TG, Egging M, Voorhorst FJ, Steenbergen RD, van der Linden HC, Risse EK, Berkhof J, de Vries EG, van der Zee AG, Postmus PE, et al. Elevated hTERT mRNA levels: a potential determinant of bronchial squamous cell carcinoma (in situ). Int J Cancer 2004; 109: 41217.
  • 75
    Lantuejoul S, Soria JC, Morat L, Lorimier P, Moro-Sibilot D, Sabatier L, Brambilla C, Brambilla E. Telomere shortening and telomerase reverse transcriptase expression in preinvasive bronchial lesions. Clin Cancer Res 2005; 11: 207482.
  • 76
    Meeker AK, van Heek TN, Kern SE, Yeo CJ, Lillemoe KD, Cameron JL, Offerhaus GJ, Hicks JL, Wilentz RE, Goggins MG, De Marzo AN, Hruban RH, Maitra A. Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol 2002; 161: 15417.
  • 77
    Lin KW, Yan J. The telomere length dynamic and methods of its assessment. J Cell Biol Med 2005; 9: 97789.
  • 78
    Baird DM. New developments in telomere length analysis. Exp Gerontol 2005; 40: 3638.
  • 79
    Albanell J, Bosl GJ, Reuter VE, Engelhardt M, Franco S, Moore MA, Dmitrovsky E. Telomerase activity in germ cell cancers and mature teratomas. J Natl Cancer Inst 1999; 91: 13216.
  • 80
    Hirashima T, Komiya T, Nitta T, Takada Y, Kobayashi M, Masuda N, Matui K, Takada M, Kikui M, Yasumitu T, Ohno A, Nakagawa K, et al. Prognostic significance of telomeric repeat length alterations in pathological stage I-IIIA non-small cell lung cancer. Anticancer Res 2000; 20: 21817.
  • 81
    Olaussen KA, Dubrana K, Domont J, Spano JP, Sabatier L, Soria JC. Telomeres and telomerase as targets for anticancer drug development. Crit Rev Oncol Hematol 2006; 57: 191214.
  • 82
    Damm K, Hemmann U, Garin-Chesa P, Hauel N, Kauffmann I, Priepke H, Niestroj C, Daiber C, Enenkal B, Guilliard B, Lauritsch I, Muller E, Pascolo E, Sauter G, Pantic M, Mortens UM, Wenz C, Lingnes J, Kraut N, Rettig WJ, Schnapp A. A highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO J 2001; 20: 695868.
  • 83
    Hayakawa N, Nozawa K, Ogawa A, Kato N, Yoshida K, Akamatsu K, Tsuchiya M, Nagasaka A, Yoshida S. Isothiazolone derivatives selectively inhibit telomerase from human and rat cancer cells in vitro. Biochemistry 1999; 38: 115017.
  • 84
    Naasani I, Seimiya H, Yamori T, Tsuruo T. FJ5002: a potent telomerase inhibitor identified by exploiting the disease-oriented screening program with COMPARE analysis. Cancer Res 1999; 59: 4000411.
  • 85
    Kosciolek BA, Kalantidis K, Tabler M, Rowley PT. Inhibition of telomerase activity in human cancer cells by RNA interference. Mol Cancer Ther 2003; 2: 20916.
  • 86
    Lu XD, Qin WX, Pan DN, Li JJ, Wan DF, Wen CJ, Li CJ, Gu JR, Yang SL. A DNA vector-based RNAi technology to inhibit the activity of the telomerase of cell line HCCLM3. Zhonhua Yi Xue Za Zhi 2004; 84: 13815.
  • 87
    Dikmen ZG, Gellert GC, Jackson S, Gryaznov S, Tressler R, Dogan P, Wright WE, Shay JW. In vivo inhibition of lung cancer GNR163L: a novel human telomerase inhibitor. Cancer Res 2005; 65: 786673.
  • 88
    Misawa M, Tauchi T, Sashida G, Nakajima A, Abe K, Ohyashiki JH, Ohyashiki K. Inhibition of human telomerase enhances the effect of chemotherapeutic agents in lung cancer cells. Int J Oncol 2002; 21: 108792.
  • 89
    Gowan SM, Harrison JR, Patterson L, Valenti M, Read MA, Neidle S, Kelland LR. A G-quadruplex interactive potent small-molecule inhibitor of telomerase exhibiting in vitro and in vivo antitumor activity. Mol Pharmacol 2002; 61: 115462.
  • 90
    Shammas MA, Liu X, Gavory G, Raney KD, Balasubramanian S, Shmookler Reis RJ. Targeting the single strand G-rich overhang of telomeres with PNA inhibits cell growth and induces apoptosis of human immortal cells. Exp Cell Res 2004; 295: 20414.